A Neurodevelopment Approach for a Transitional Model of Early Onset Schizophrenia
暂无分享,去创建一个
[1] C. Limperopoulos,et al. Prenatal origins of neuropsychiatric diseases , 2021, Acta paediatrica.
[2] Jacob J. Crouse,et al. Predicting the emergence of full-threshold bipolar I, bipolar II and psychotic disorders in young people presenting to early intervention mental health services , 2020, Psychological Medicine.
[3] Ajit Kumar,et al. Do Psychological Interventions Work for Psychosis in Adolescents? , 2020, Schizophrenia bulletin.
[4] S. Wood,et al. Adding a Dimension to the Dichotomy: Affective Processes Are Implicated in the Relationship Between Autistic and Schizotypal Traits , 2020, Frontiers in Psychiatry.
[5] A. Tanskanen,et al. Comparative Effectiveness of Antipsychotics for Risk of Attempted or Completed Suicide Among Persons With Schizophrenia , 2020, Schizophrenia bulletin.
[6] E. Levin,et al. Beyond the looking glass: recent advances in understanding the impact of environmental exposures on neuropsychiatric disease , 2020, Neuropsychopharmacology.
[7] G. Kirov,et al. Genetic association of FMRP targets with psychiatric disorders , 2020, bioRxiv.
[8] Ariana E. Anderson,et al. Synaptic and Gene Regulatory Mechanisms in Schizophrenia, Autism, and 22q11.2 Copy Number Variant–Mediated Risk for Neuropsychiatric Disorders , 2020, Biological Psychiatry.
[9] M. Leboyer,et al. Early and very early‐onset schizophrenia compared with adult‐onset schizophrenia: French FACE‐SZ database , 2020, Brain and behavior.
[10] P. Allard,et al. An Understudied Dimension: Why Age Needs to Be Considered When Studying Epigenetic-Environment Interactions , 2020, Epigenetics insights.
[11] S. Baron-Cohen,et al. Autistic traits in adults who have attempted suicide , 2019, Molecular Autism.
[12] 住吉 太幹,et al. Specificity and continuity of schizophrenia and bipolar disorder : relation to biomarkers , 2019 .
[13] Manish Aligeti,et al. Off-Label Use of Clozapine in Children and Adolescents—A Literature Review , 2019, American journal of therapeutics.
[14] C. Pariante,et al. Early-Life Adversity, Systemic Inflammation and Comorbid Physical and Psychiatric Illnesses of Adult Life. , 2019, Current topics in behavioral neurosciences.
[15] N. Malas,et al. Addressing mental health stigma: A pilot educational video intervention for caregivers to facilitate psychiatric consultation in inpatient pediatric care settings , 2019, Clinical child psychology and psychiatry.
[16] G. Cagney,et al. Epigenetic Factors in Schizophrenia: Mechanisms and Experimental Approaches , 2019, Molecular Neuropsychiatry.
[17] P. Das,et al. Understanding suicide: Focusing on its mechanisms through a lithium lens. , 2018, Journal of affective disorders.
[18] E. de la Serna,et al. Characterization of children and adolescents with psychosis risk syndrome: The Children and Adolescents Psychosis Risk Syndrome (CAPRIS) study , 2018, Early intervention in psychiatry.
[19] F. Mancini,et al. Prevalence and Clinical Significance of Symptoms at Ultra High Risk for Psychosis in Children and Adolescents with Obsessive–Compulsive Disorder: Is There an Association with Global, Role, and Social Functioning? , 2018, Brain sciences.
[20] Fabien Ringeval,et al. An emotional modulation model as signature for the identification of children developmental disorders , 2018, Scientific Reports.
[21] S. Lawrie,et al. Using Online Screening in the General Population to Detect Participants at Clinical High-Risk for Psychosis , 2018, Schizophrenia bulletin.
[22] I. Baeza,et al. Clinical high risk for psychosis in children and adolescents: a systematic review , 2018, European Child & Adolescent Psychiatry.
[23] Jakob Grove,et al. Common schizophrenia alleles are enriched in mutation-intolerant genes and in regions under strong background selection , 2018, Nature Genetics.
[24] Armin Raznahan,et al. Neuroanatomical phenotypes in mental illness: identifying convergent and divergent cortical phenotypes across autism, ADHD and schizophrenia. , 2018, Journal of psychiatry & neuroscience : JPN.
[25] B. Rund. The research evidence for schizophrenia as a neurodevelopmental disorder. , 2018, Scandinavian journal of psychology.
[26] K. Hall,et al. Neuroleptic Malignant Syndrome: Diagnosis and Management. , 2018, The primary care companion for CNS disorders.
[27] M. DelBello,et al. Efficacy and Safety of Lurasidone in Children and Adolescents With Bipolar I Depression: A Double-Blind, Placebo-Controlled Study. , 2017, Journal of the American Academy of Child and Adolescent Psychiatry.
[28] D. Weinberger,et al. Genetic insights into the neurodevelopmental origins of schizophrenia , 2017, Nature Reviews Neuroscience.
[29] D. Weinberger. Future of Days Past: Neurodevelopment and Schizophrenia. , 2017, Schizophrenia bulletin.
[30] S. Leucht,et al. Efficacy, acceptability, and tolerability of antipsychotics in children and adolescents with schizophrenia: A network meta-analysis , 2017, European Neuropsychopharmacology.
[31] L. Seidman,et al. Evolving Notions of Schizophrenia as a Developmental Neurocognitive Disorder , 2017, Journal of the International Neuropsychological Society.
[32] S. Jeon,et al. Unresolved Issues for Utilization of Atypical Antipsychotics in Schizophrenia: Antipsychotic Polypharmacy and Metabolic Syndrome , 2017, International journal of molecular sciences.
[33] M. Pontillo,et al. An Overview of Recent Findings on Social Anxiety Disorder in Adolescents and Young Adults at Clinical High Risk for Psychosis , 2017, Brain sciences.
[34] S. Ehrlich,et al. Need for a more developmental perspective: QTc prolongation under psychotropic medication , 2017, European Child & Adolescent Psychiatry.
[35] R. Rosenheck,et al. Demographic and clinical correlates of substance use disorders in first episode psychosis , 2017, Schizophrenia Research.
[36] A. Carvalho,et al. Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review , 2017, Therapeutics and clinical risk management.
[37] J. van os,et al. A critique of the “ultra‐high risk” and “transition” paradigm , 2017, World psychiatry : official journal of the World Psychiatric Association.
[38] A. Green,et al. The link between schizophrenia and substance use disorder: A unifying hypothesis , 2017, Schizophrenia Research.
[39] F. Berna,et al. Abstract and experiential thinking differentially account for anomalous perception of reality in people with or without schizophrenia , 2017, Schizophrenia Research.
[40] M. Kundakovic,et al. The Epigenetic Link between Prenatal Adverse Environments and Neurodevelopmental Disorders , 2017, Genes.
[41] R. McIntyre,et al. Diagnostic clusters associated with an early onset schizophrenia diagnosis among children and adolescents , 2017, Human psychopharmacology.
[42] A. Barr,et al. Antipsychotic Induced Dopamine Supersensitivity Psychosis: A Comprehensive Review , 2016, Current neuropharmacology.
[43] Wei Cheng,et al. Contribution of copy number variants to schizophrenia from a genome-wide study of 41,321 subjects , 2016, Nature Genetics.
[44] G. Bersani,et al. Cannabis use related to early psychotic onset: Role of premorbid function , 2016, Neuroscience Letters.
[45] Giulio Genovese,et al. Increased burden of ultra-rare protein-altering variants among 4,877 individuals with schizophrenia , 2016, Nature Neuroscience.
[46] G. Faa,et al. Fetal programming of neuropsychiatric disorders. , 2016, Birth defects research. Part C, Embryo today : reviews.
[47] D. Collier,et al. Analysis of Intellectual Disability Copy Number Variants for Association With Schizophrenia. , 2016, JAMA psychiatry.
[48] M. De Hert,et al. Aripiprazole and Acute Extrapyramidal Symptoms in Children and Adolescents: A Meta-Analysis , 2016, CNS Drugs.
[49] C. Correll,et al. Clinical Characteristics and Predictors of Outcome of Schizophrenia-Spectrum Psychosis in Children and Adolescents: A Systematic Review. , 2016, Journal of child and adolescent psychopharmacology.
[50] M. Knapp,et al. Early intervention for first‐episode psychosis: broadening the scope of economic estimates , 2016, Early intervention in psychiatry.
[51] Dennis R. Grayson,et al. Altering the course of schizophrenia: progress and perspectives , 2016, Nature Reviews Drug Discovery.
[52] T. Kishimoto,et al. Attenuated psychotic and basic symptom characteristics in adolescents with ultra-high risk criteria for psychosis, other non-psychotic psychiatric disorders and early-onset psychosis , 2016, European Child & Adolescent Psychiatry.
[53] C. Spencer,et al. A contribution of novel CNVs to schizophrenia from a genome-wide study of 41,321 subjects: CNV Analysis Group and the Schizophrenia Working Group of the Psychiatric Genomics Consortium , 2016, bioRxiv.
[54] S. Stahl,et al. A review of the current nomenclature for psychotropic agents and an introduction to the Neuroscience-based Nomenclature , 2015, European Neuropsychopharmacology.
[55] M. Olfson,et al. Antipsychotic treatment of adults in the United States. , 2015, The Journal of clinical psychiatry.
[56] Christopher S. Poultney,et al. Insights into Autism Spectrum Disorder Genomic Architecture and Biology from 71 Risk Loci , 2015, Neuron.
[57] G. Kirov,et al. Common alleles contribute to schizophrenia in CNV carriers , 2015, Molecular Psychiatry.
[58] S. Wood,et al. The association between autism and schizophrenia spectrum disorders: A review of eight alternate models of co-occurrence , 2015, Neuroscience & Biobehavioral Reviews.
[59] R. Ophoff,et al. Genome-wide burden of deleterious coding variants increased in schizophrenia , 2015, Nature Communications.
[60] M. Pontillo,et al. OPINION Psychosocial interventions for very early and early- onset schizophrenia: a review of treatment efficacy , 2015 .
[61] G. Kirov,et al. Novel Findings from CNVs Implicate Inhibitory and Excitatory Signaling Complexes in Schizophrenia , 2015, Neuron.
[62] M. DelBello,et al. Olanzapine/Fluoxetine combination in children and adolescents with bipolar I depression: a randomized, double-blind, placebo-controlled trial. , 2015, Journal of the American Academy of Child and Adolescent Psychiatry.
[63] M. Nordentoft,et al. EPA guidance on the early detection of clinical high risk states of psychoses , 2015, European Psychiatry.
[64] R. Kahn,et al. Extrapyramidal symptoms during treatment of first schizophrenia episode: Results from EUFEST , 2014, European Neuropsychopharmacology.
[65] Seungtai Yoon,et al. De novo Mutations in Schizophrenia Implicate Chromatin Remodeling and Support a Genetic Overlap with Autism and Intellectual Disability , 2014, Molecular Psychiatry.
[66] G. Kirov,et al. The Penetrance of Copy Number Variations for Schizophrenia and Developmental Delay , 2014, Biological Psychiatry.
[67] J. Bartlett. Childhood-onset schizophrenia: what do we really know? , 2014, Health psychology and behavioral medicine.
[68] J. Rapoport,et al. Childhood onset schizophrenia and early onset schizophrenia spectrum disorders. , 2013, Child and adolescent psychiatric clinics of North America.
[69] Stephen J. Guter,et al. Co‐occurrence of autism, childhood psychosis, and intellectual disability associated with a de novo 3q29 microdeletion , 2013, American journal of medical genetics. Part A.
[70] K. Gadow. Association of schizophrenia spectrum and autism spectrum disorder (ASD) symptoms in children with ASD and clinic controls. , 2013, Research in developmental disabilities.
[71] D. Vancampfort,et al. Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders--a systematic review and meta-analysis. , 2013, Schizophrenia bulletin.
[72] K. Gadow. Schizophrenia spectrum and attention-deficit/hyperactivity disorder symptoms in autism spectrum disorder and controls. , 2012, Journal of the American Academy of Child and Adolescent Psychiatry.
[73] A. Petronis,et al. Epigenetics of major psychosis: progress, problems and perspectives. , 2012, Trends in genetics : TIG.
[74] Michael F. Green,et al. Social cognition in schizophrenia, Part 2: 12-month stability and prediction of functional outcome in first-episode patients. , 2012, Schizophrenia bulletin.
[75] Michael F. Green,et al. Social cognition in schizophrenia, Part 1: performance across phase of illness. , 2012, Schizophrenia bulletin.
[76] Peter B. Jones,et al. Extrapyramidal motor side-effects of first- and second-generation antipsychotic drugs. , 2012, The British journal of psychiatry : the journal of mental science.
[77] John M. Davis,et al. Putting the efficacy of psychiatric and general medicine medication into perspective: review of meta-analyses , 2012, British Journal of Psychiatry.
[78] S Purcell,et al. De novo CNV analysis implicates specific abnormalities of postsynaptic signalling complexes in the pathogenesis of schizophrenia , 2011, Molecular Psychiatry.
[79] S. Patten,et al. Treatment recommendations for extrapyramidal side effects associated with second-generation antipsychotic use in children and youth. , 2011, Paediatrics & child health.
[80] A. Zuddas,et al. Second generation antipsychotics (SGAs) for non-psychotic disorders in children and adolescents: A review of the randomized controlled studies , 2011, European Neuropsychopharmacology.
[81] Jong H. Yoon,et al. General and Specific Functional Connectivity Disturbances in First-Episode Schizophrenia During Cognitive Control Performance , 2011, Biological Psychiatry.
[82] M. Rutter. Research review: Child psychiatric diagnosis and classification: concepts, findings, challenges and potential. , 2011, Journal of child psychology and psychiatry, and allied disciplines.
[83] J. Rapoport,et al. Childhood onset schizophrenia: support for a progressive neurodevelopmental disorder , 2011, International Journal of Developmental Neuroscience.
[84] H. Engeland,et al. Overlap of autistic and schizotypal traits in adolescents with Autism Spectrum Disorders , 2011, Schizophrenia Research.
[85] G. Masi,et al. Management of Schizophrenia in Children and Adolescents , 2011, Drugs.
[86] M. Copenhaver,et al. A 6-week, randomized, double-blind, placebo-controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia. , 2009, Journal of child and adolescent psychopharmacology.
[87] Bart P F Rutten,et al. Epigenetic mediation of environmental influences in major psychotic disorders. , 2009, Schizophrenia bulletin.
[88] P. Visscher,et al. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder , 2009, Nature.
[89] J. Boden,et al. Outcomes for 236 patients from a 2‐year early intervention in psychosis service , 2009, Acta psychiatrica Scandinavica.
[90] Jolene R. Bostwick,et al. Antipsychotic‐Induced Hyperprolactinemia , 2009, Pharmacotherapy.
[91] R. Rosenheck,et al. A meta-analysis of the risk of acute extrapyramidal symptoms with intramuscular antipsychotics for the treatment of agitation. , 2008, The Journal of clinical psychiatry.
[92] R. Findling,et al. A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. , 2008, The American journal of psychiatry.
[93] E. Walker,et al. Childhood and current autistic features in adolescents with schizotypal personality disorder , 2008, Schizophrenia Research.
[94] Donard S Dwyer,et al. Antipsychotic Drugs: Comparison in Animal Models of Efficacy, Neurotransmitter Regulation, and Neuroprotection , 2008, Pharmacological Reviews.
[95] A. Singleton,et al. Rare Structural Variants Disrupt Multiple Genes in Neurodevelopmental Pathways in Schizophrenia , 2008, Science.
[96] P. Kulhara,et al. Early intervention in schizophrenia , 2008, Indian journal of psychiatry.
[97] Kiralee M. Hayashi,et al. Dynamic mapping of cortical development before and after the onset of pediatric bipolar illness. , 2007, Journal of child psychology and psychiatry, and allied disciplines.
[98] Deanna Greenstein,et al. Cortical brain development in nonpsychotic siblings of patients with childhood-onset schizophrenia. , 2007, Archives of general psychiatry.
[99] Robert Freedman,et al. Deconstructing schizophrenia: an overview of the use of endophenotypes in order to understand a complex disorder. , 2006, Schizophrenia bulletin.
[100] J. Rapoport,et al. Childhood onset schizophrenia: cortical brain abnormalities as young adults. , 2006, Journal of child psychology and psychiatry, and allied disciplines.
[101] R. Kahn,et al. The 22q11.2 deletion in children: high rate of autistic disorders and early onset of psychotic symptoms. , 2006, Journal of the American Academy of Child and Adolescent Psychiatry.
[102] M. Rutter,et al. Continuities and discontinuities in psychopathology between childhood and adult life. , 2006, Journal of child psychology and psychiatry, and allied disciplines.
[103] S. Strakowski,et al. Open-label lithium for the treatment of adolescents with bipolar depression. , 2006, Journal of the American Academy of Child and Adolescent Psychiatry.
[104] A. Yung,et al. Mapping the Onset of Psychosis: The Comprehensive Assessment of At-Risk Mental States , 2005 .
[105] T. Kircher,et al. EASE: Examination of Anomalous Self-Experience , 2005, Psychopathology.
[106] J. Lieberman,et al. Antipsychotic drug effects on brain morphology in first-episode psychosis. , 2005, Archives of general psychiatry.
[107] Thomas F. Nugent,et al. Dynamic mapping of human cortical development during childhood through early adulthood. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[108] A. Addington,et al. Pervasive developmental disorder and childhood-onset schizophrenia: comorbid disorder or a phenotypic variant of a very early onset illness? , 2004, Biological Psychiatry.
[109] C. McDougle,et al. Risperidone in children with autism and serious behavioral problems. , 2002, The New England journal of medicine.
[110] Richie Poulton,et al. Evidence for early-childhood, pan-developmental impairment specific to schizophreniform disorder: results from a longitudinal birth cohort. , 2002, Archives of general psychiatry.
[111] J. Rapoport,et al. Mapping adolescent brain change reveals dynamic wave of accelerated gray matter loss in very early-onset schizophrenia , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[112] J. Rapoport,et al. Update on childhood-onset schizophrenia , 2000, Current psychiatry reports.
[113] B. Barraclough,et al. Causes of the excess mortality of schizophrenia. , 2000, The British journal of psychiatry : the journal of mental science.
[114] B. Dickey,et al. Persons with dual diagnoses of substance abuse and major mental illness: their excess costs of psychiatric care. , 1996, American journal of public health.
[115] D. Kivlahan,et al. Treatment cost and rehospitalization rate in schizophrenic outpatients with a history of substance abuse. , 1991, Hospital & community psychiatry.
[116] G Huber,et al. The concept of basic symptoms in schizophrenic and schizoaffective psychoses. , 1989, Recenti progressi in medicina.
[117] A. David,et al. The nature of overinclusive thinking in schizophrenia. , 1987, Psychopathology.
[118] D. Weinberger. Implications of normal brain development for the pathogenesis of schizophrenia. , 1987, Archives of general psychiatry.
[119] F. Mastaglia,et al. Neuroleptic malignant syndrome , 1984, The Medical journal of Australia.
[120] E. Bleuler. [Dementia praecox or the group of schizophrenias]. , 1968, Vertex.
[121] G. Martinotti,et al. [Clinical use of lithium and new retard formulation: results of a survey on italian psychiatrists]. , 2020, Rivista di psichiatria.
[122] J. Sebat,et al. Joint Contributions of Rare Copy Number Variants and Common SNPs to Risk for Schizophrenia. , 2019, The American journal of psychiatry.
[123] N. Kanahara,et al. Antipsychotic-Induced Dopamine Supersensitivity Psychosis: Pharmacology, Criteria, and Therapy , 2017, Psychotherapy and Psychosomatics.
[124] T. van Amelsvoort,et al. [Transitional psychiatry in the Netherlands: experiences and views of mental health professionals]. , 2017, Tijdschrift voor psychiatrie.
[125] J. Rapoport,et al. Common polygenic variation and risk for childhood-onset schizophrenia , 2016, Molecular Psychiatry.
[126] C. Correll,et al. Corrected QT changes during antipsychotic treatment of children and adolescents: a systematic review and meta-analysis of clinical trials. , 2015, Journal of the American Academy of Child and Adolescent Psychiatry.
[127] M. Owen,et al. schizophrenia-associated loci Analysis of copy number variations at 15 , 2014 .
[128] Ian M. Anderson,et al. Antipsychotic-Related QTc Prolongation, Torsade de Pointes and Sudden Death , 2012, Drugs.
[129] Swapnil Gupta,et al. What is schizophrenia: A neurodevelopmental or neurodegenerative disorder or a combination of both? A critical analysis , 2010, Indian journal of psychiatry.
[130] Deanna Greenstein,et al. Autism spectrum disorders and childhood-onset schizophrenia: clinical and biological contributions to a relation revisited. , 2009, Journal of the American Academy of Child and Adolescent Psychiatry.
[131] P. Visscher,et al. Rare chromosomal deletions and duplications increase risk of schizophrenia , 2008, Nature.
[132] S. Kapur. Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. , 2003, The American journal of psychiatry.
[133] A. Yung,et al. The prodromal phase of first-episode psychosis: past and current conceptualizations. , 1996, Schizophrenia bulletin.
[134] D. Levinson,et al. Prevalence of substance abuse in schizophrenia: demographic and clinical correlates. , 1990, Schizophrenia bulletin.
[135] L. Bender. Childhood schizophrenia; clinical study on one hundred schizophrenic children. , 1947, The American journal of orthopsychiatry.